Abegrin (etaracizumab) / AstraZeneca - LARVOL DELTA

Arming tumor-associated macrophages to inhibit cancer progression (AACR 2024) - "In the 1990s, a humanized anti-αvβ3 antibody (Etaracizumab) was developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity...Here we define an "antigen-effector cell matching" strategy that allows for maximal anti-tumor activity for various drug resistant epithelial cancers. ABT101 will enter clinical trials for patients with drug resistant lung cancer in the first quarter of 2024."

Lung Cancer • Oncology • Solid Tumor

Macrophage-Engaging IgG4 Antibody Triggers Cytotoxicity Against Integrin αvβ3+ Cancers. (PubMed, Mol Cancer Ther) - "The humanized IgG1 anti-αvβ3 antibody, etaracizumab, was originally developed to exploit NK cell-mediated cytotoxicity against αvβ3-positive tumors...Mechanistically, this enhancement was driven by CD64 activation in TAMs, leading to robust upregulation of inducible nitric oxide synthase (iNOS), a pivotal enzyme for immune effector-mediated cytotoxicity. Our findings reveal a powerful strategy for targeting highly aggressive, drug-resistant integrin αvβ3-positive tumors by harnessing TAMs for antibody-mediated cancer therapy, and demonstrate that this Fc switch approach may be broadly applicable to other targets in TAM-enriched tumor microenvironments."

Journal • Lung Cancer • Oncology • Solid Tumor